Cite
APA Citation
Sada, M., Watanabe, M., Inui, T., Nakamoto, K., Hirata, A., Nakamura, M., Honda, K., Saraya, T., Kurai, D., Kimura, H., Ishii, H., & Takizawa, H. (2021). ruxolitinib inhibits poly(I:C) and type 2 cytokines‐induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma. Immunity, inflammation and disease, 9(2), 363–373. http://access.bl.uk/ark:/81055/vdc_100130247822.0x000012